theophylline monohydrate (Q47495785)

significant drug interaction

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lithium

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vemurafenib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

subject has role

phosphodiesterase inhibitors

1 reference

5 March 2018

C872

1 reference

InChI=1S/C7H8N4O2.H2O/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;/h3H,1-2H3,(H,8,9);1H2

UNII

C137DTR5RG

retrieved

25 January 2018

Identifiers

InChI

1 reference

25 January 2018

INQSMEFCAIHTJG-UHFFFAOYSA-N

1 reference

25 January 2018

2 references

https://commonchemistry.cas.org/detail?cas_rn=5967-84-0

25 January 2018

6 April 2021

InChIKey

INQSMEFCAIHTJG-UHFFFAOYSA-N

1 reference

25 January 2018

1 reference

25 January 2018

1 reference

1 reference

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

611-861-2

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.629

retrieved

27 December 2018

title

1H-Purine-2,6-dione, 3,9-dihydro-1,3-dimethyl-, hydrate (1:1) (English)

quotation

CAS no.: 5967-84-0 (English)

ECHA Substance Infocard ID

100.110.629

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.629

retrieved

27 December 2018

title

1H-Purine-2,6-dione, 3,9-dihydro-1,3-dimethyl-, hydrate (1:1) (English)

quotation

CAS no.: 5967-84-0 (English)

AICS Chemical ID (BEING DELETED)

0 references

1 reference

25 January 2018

1 reference